Exelixis, Inc. (EXEL) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript

Company Overview - Exelixis has been established for over 25 years and is primarily known for its product CABOMETYX [2] - CABOMETYX was launched for second-line renal cell carcinoma (RCC) in spring 2016 and has since expanded to include 7 to 8 different indications, primarily in RCC and recently in neuroendocrine tumors, which was launched in the second quarter of this year [2]